Discover undervalued stocks with Eulerpool.

Subscribe for $2

Zynex Stock ZYXI

Price

0
Today +/-
-0
Today %
-0 %

Zynex stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Zynex stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Zynex stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Zynex stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Zynex's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Zynex Stock Price History

DateZynex Price
10/17/20250 undefined
10/17/20251.33 undefined
10/16/20251.38 undefined
10/15/20251.40 undefined
10/14/20251.37 undefined
10/13/20251.39 undefined
10/10/20251.38 undefined
10/10/20251.36 undefined
10/9/20251.44 undefined
10/8/20251.49 undefined
10/7/20251.44 undefined
10/6/20251.47 undefined
10/3/20251.49 undefined
10/2/20251.46 undefined
10/1/20251.45 undefined
9/30/20251.46 undefined
9/28/20251.47 undefined
9/25/20251.45 undefined
9/24/20251.47 undefined
9/24/20251.51 undefined
9/23/20251.62 undefined
9/22/20251.61 undefined

Zynex Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Zynex, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Zynex from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Zynex’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Zynex. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Zynex’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Zynex’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Zynex’s growth potential.

Zynex Revenue, EBIT and net profit per share

DateZynex RevenueZynex EBITZynex Net Income
2030e148.51 M undefined0 undefined2.16 M undefined
2029e135.86 M undefined-714,000 undefined-4.02 M undefined
2028e124.13 M undefined-7.75 M undefined-8.65 M undefined
2027e122.22 M undefined-4.95 M undefined-5.72 M undefined
2026e103.5 M undefined-16.98 M undefined-13.8 M undefined
2025e96.67 M undefined-35.49 M undefined-40.69 M undefined
2024192.35 M undefined5.99 M undefined2.99 M undefined
2023184.32 M undefined10.78 M undefined9.73 M undefined
2022158.2 M undefined22.9 M undefined17 M undefined
2021130.3 M undefined22.4 M undefined17.1 M undefined
202080.1 M undefined10.3 M undefined9.1 M undefined
201945.5 M undefined11.1 M undefined9.5 M undefined
201831.9 M undefined10.4 M undefined9.6 M undefined
201723.4 M undefined8.9 M undefined7.4 M undefined
201613.3 M undefined600,000 undefined100,000 undefined
201511.6 M undefined-2.5 M undefined-2.9 M undefined
201411.1 M undefined-7.9 M undefined-6.2 M undefined
201321.7 M undefined-7.6 M undefined-7.3 M undefined
201239.7 M undefined2.7 M undefined1.6 M undefined
201134.1 M undefined3.1 M undefined1.6 M undefined
201024.1 M undefined1.6 M undefined400,000 undefined
200918.7 M undefined3.8 M undefined2.4 M undefined
200811.8 M undefined300,000 undefined100,000 undefined
20078 M undefined3.2 M undefined2.1 M undefined
20062.6 M undefined-200,000 undefined-300,000 undefined
20052.1 M undefined200,000 undefined300,000 undefined

Zynex Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
DIV. ()
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
112281118243439211111132331458013015818419296103122124135148
--100.00-300.0037.5063.6433.3341.6714.71-46.15-47.62-18.1876.9234.7845.1677.7862.5021.5416.464.35-50.007.2918.451.648.879.63
15,300.00100.00100.00100.0087.5081.8277.7875.0076.4776.9261.9027.2754.5569.2378.2680.6580.0078.7579.2379.7579.3579.69159.38148.54125.41123.39113.33103.38
012279141826301336918253663103126146153000000
0-100202011-7-6-207999171792-40-13-5-8-42
-----------800.00-14.29-66.67--28.57--88.89--47.06-77.78-2,100.00-67.50-61.5460.00-50.00-150.00
---------------------------0.02
----------------------------
24.42525.926.431.333.733.433.834.134.334.334.334.434.436.537.437.438.439.239.136.1432.3000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Zynex Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Zynex is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (k)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (k)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (k)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                           
0000.3000.90.60.80.80.30.100.25.610.11439.242.620.144.5839.63
0.20.20.71.34.55.657.31112.273.22.432.22.85.813.828.635.126.8418.02
0001000000009003000000000000
0.20.30.50.60.92.22.13.64.66.251.90.30.10.40.82.48.610.813.513.1113.92
0000.20.30.810.91.72.10.40.3000.20.60.31.40.70.93.333.61
0.40.51.22.55.78.6912.418.121.313.65.82.73.38.414.322.56382.769.687.8575.18
0.10.20.30.30.92.12.62.93.43.72.91.30.80.60.23.94.98.218.915.316.2214.05
0000000000000000000000
0000000000000000000000
0000000000.30.20.10.100000109.18.167.25
0000000000.30000000020.420.420.420.4
000000.10.20.30.30.30.400.10.10.410.80.91.32.24.275.21
0.10.20.30.30.92.22.83.23.74.63.51.410.70.64.95.79.150.64749.0546.9
0.50.71.52.86.610.811.815.621.825.917.17.23.74919.228.272.1133.3116.6136.9122.08
                                           
000000000000000000003332
01.31.52.42.63.74.44.75.15.55.65.75.867.68.29.237.280.482.490.8893.09
-0.2-1.2-0.9-1.211.13.13.456.6-0.7-6.9-9.8-9.8-2.44.914.423.401726.7829.77
0000000000000000000000
0000000000000000000000
-0.20.10.61.23.64.87.58.110.112.14.9-1.2-4-3.85.213.123.660.680.499.4117.69122.89
0.10.20.30.30.811.11.32.22.12.72.52.52.92.31.62.14.74.75.68.437.09
0.10.20.10.30.71.81.21.62.32.20.90.80.80.90.51.6356.889.279.49
00000.90.70.91.31.91.80.10.20.210.93.80.10.35.920.630
00000.11.901.33.35.95.84.442.800000000
0.20.10.20.50.40.10.10.10.10.10.10.10.10.10.4000.15.55.50.20.29
0.40.50.61.12.95.53.35.69.812.19.687.67.74.175.210.122.921.118.5316.86
00.10.30.300.100.30.30.10.20.30.20.1000.10.310.95.558.0659.36
00010010040050020050080010000000000000
0000000.51.51.20.92.5000033.34.925.623.514.1810.15
00.10.30.40.10.51221.82.80.30.20.1033.45.236.52972.2469.51
0.40.60.91.5364.37.611.813.912.48.37.87.84.1108.615.359.450.190.7786.37
0.20.71.52.76.610.811.815.721.92617.37.13.849.323.132.275.9139.8149.5208.47209.27
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Zynex provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Zynex's financial health and stability.

Assets

Zynex's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Zynex must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Zynex after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Zynex's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (k)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0000202011-7-6-20799917179
000000000000000001234
00000000001,000000000000-2,000
00-10-6-9-57-3-3-42510-10-4-12-15-95
0000585821120111105452
000000000000000000000
000000110100000020366
0-1000030000001896061317
00000-100-1000000-10000-1
00000-100-1-100000-100-1600
000000000000000000-1600
000000000000000000000
000001-11120-10-1-200015-546
010000000000000-3025-2-26-37
010002-10120-10-1-2-3-22513-357
---------------------
0000000000000000-200-30
00000000000000543253-2224
0.18-1.11-0.24-0.630-2.172.69-1.34-1.63-1.64-1.020.690.341.548.178.336.14-0.176.3413.3316.55
000000000000000000000

Zynex stock margins

The Zynex margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zynex. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zynex.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Zynex's sales revenue. A higher gross margin percentage indicates that the Zynex retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Zynex's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Zynex's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Zynex's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Zynex. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Zynex's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Zynex Margin History

Zynex Gross marginZynex Profit marginZynex EBIT marginZynex Profit margin
2030e79.7 %0 %1.46 %
2029e79.7 %-0.53 %-2.96 %
2028e79.7 %-6.25 %-6.97 %
2027e79.7 %-4.05 %-4.68 %
2026e79.7 %-16.41 %-13.34 %
2025e79.7 %-36.71 %-42.1 %
202479.7 %3.11 %1.56 %
202379.38 %5.85 %5.28 %
202279.96 %14.48 %10.75 %
202179.36 %17.19 %13.12 %
202079.15 %12.86 %11.36 %
201980.88 %24.4 %20.88 %
201881.19 %32.6 %30.09 %
201779.49 %38.03 %31.62 %
201673.68 %4.51 %0.75 %
201557.76 %-21.55 %-25 %
201431.53 %-71.17 %-55.86 %
201362.21 %-35.02 %-33.64 %
201277.83 %6.8 %4.03 %
201178.59 %9.09 %4.69 %
201078.42 %6.64 %1.66 %
200979.68 %20.32 %12.83 %
200880.51 %2.54 %0.85 %
200790 %40 %26.25 %
200688.46 %-7.69 %-11.54 %
200595.24 %9.52 %14.29 %

Zynex Stock Sales Revenue, EBIT, Earnings per Share

The Zynex earnings per share therefore indicates how much revenue Zynex has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zynex earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zynex's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zynex’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zynex's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Zynex Revenue, EBIT and net profit per share

DateZynex Sales per ShareZynex EBIT per shareZynex Earnings per Share
2030e4.9 undefined0 undefined0.07 undefined
2029e4.48 undefined-0.02 undefined-0.13 undefined
2028e4.1 undefined-0.24 undefined-0.29 undefined
2027e4.03 undefined-0.15 undefined-0.19 undefined
2026e3.42 undefined-0.53 undefined-0.46 undefined
2025e3.19 undefined-1.1 undefined-1.34 undefined
20245.96 undefined0.19 undefined0.09 undefined
20235.1 undefined0.3 undefined0.27 undefined
20224.05 undefined0.59 undefined0.43 undefined
20213.32 undefined0.57 undefined0.44 undefined
20202.09 undefined0.27 undefined0.24 undefined
20191.22 undefined0.3 undefined0.25 undefined
20180.85 undefined0.28 undefined0.26 undefined
20170.64 undefined0.24 undefined0.2 undefined
20160.39 undefined0.02 undefined0 undefined
20150.34 undefined-0.07 undefined-0.08 undefined
20140.32 undefined-0.23 undefined-0.18 undefined
20130.63 undefined-0.22 undefined-0.21 undefined
20121.16 undefined0.08 undefined0.05 undefined
20111 undefined0.09 undefined0.05 undefined
20100.71 undefined0.05 undefined0.01 undefined
20090.56 undefined0.11 undefined0.07 undefined
20080.35 undefined0.01 undefined0 undefined
20070.26 undefined0.1 undefined0.07 undefined
20060.1 undefined-0.01 undefined-0.01 undefined
20050.08 undefined0.01 undefined0.01 undefined

Zynex business model

Zynex Inc is an American company that manufactures and distributes medical devices and accessories. The company was founded in 1996 and is headquartered in Englewood, Colorado. In recent years, it has become a major player in the pain therapy market. The history of Zynex began with the development of a neurotherapeutic system called NeuroMove, which aimed to restore mobility in patients with paralysis after strokes or other neurological disorders. The company uses proprietary technology to provide safe and effective electrotherapeutic stimulation, which helps trigger muscle contractions and improve mobility. Over the years, the company has specialized in the development and sale of medical devices for pain therapy and rehabilitation. Zynex's products can be used in various areas, including electrostimulation, TENS and EMS therapy, home diagnostics, as well as blood pressure and oxygen measurement. Zynex offers devices specifically for pain therapy. These devices are used by many doctors and physiotherapists to support patients in their healing process. The company's flagship product is the Nexus D-11 EMS and TENS device, which is capable of conducting multiple pain treatments simultaneously. Another important device from Zynex is the InWave system, which applies FDA-approved electromagnetic wave therapy. The therapy is used for both acute and chronic pain and aims to promote the body's natural healing processes to relieve pain. Zynex also manufactures home diagnostic devices such as the blood sugar monitor and pulse oximeter, which can be regularly used by patients at home to monitor their well-being. These products help individuals develop an understanding of how their body responds to different treatments or environmental conditions. An important aspect of Zynex's business model is collaborating with healthcare customers. The company forms partnerships with medical facilities and practitioners to ensure that its products are effectively and safely utilized. These partnerships often include training programs to ensure that users of each device develop a basic understanding of how it works to ensure quality treatment. Zynex has also established a subsidiary called Zynex Medical Europe, which operates in European regions. The company is based in the Netherlands and is responsible for marketing and distributing Zynex's products in Europe. Overall, Zynex has established itself as a key player in the field of pain therapy and rehabilitation. Through its innovative technology and healthcare partnerships, the company is able to provide the best possible patient care. Zynex is one of the most popular companies on Eulerpool.com.

Zynex SWOT Analysis

Strengths

Zynex Inc possesses a strong and experienced management team, which brings in-depth industry knowledge and expertise to the company. This enables them to make strategic decisions and navigate the competitive landscape effectively.

The company has a robust product portfolio that includes innovative medical devices, focusing on pain management and rehabilitation. This diversification allows Zynex Inc to cater to various customer needs and target multiple market segments.

Weaknesses

Zynex Inc heavily relies on a limited number of suppliers for its components and raw materials. Any disruption or issues in the supply chain could potentially impact their production and result in delayed deliveries.

The company's brand awareness and market penetration may be relatively lower compared to some of its larger competitors. This makes it challenging for Zynex Inc to capture a significant market share and compete effectively on a global scale.

Opportunities

The growing demand for pain management and rehabilitation devices presents a significant opportunity for Zynex Inc to expand its customer base and increase sales. The aging population and increasing prevalence of chronic diseases contribute to this favorable market trend.

Zynex Inc can explore strategic partnerships or collaborations with healthcare providers and institutions to enhance its distribution channels and gain access to a wider customer network. This would help increase brand visibility and drive sales growth.

Threats

Intense competition within the medical device industry poses a threat to Zynex Inc. Other established companies with greater resources and market presence may launch similar products or offer competitive pricing, potentially eroding Zynex Inc's market share.

Rapid technological advancements in the industry can also pose a threat as competitors may introduce more innovative and advanced products. Zynex Inc needs to stay ahead in terms of research and development to maintain a competitive edge.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Zynex Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Zynex historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Zynex shares outstanding

The number of shares was Zynex in 2024 — This indicates how many shares 32.299 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Zynex earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Zynex's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Zynex’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Zynex's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Zynex stock splits

In Zynex's history, there have been no stock splits.

Zynex dividend history and estimates

In 2024, Zynex paid a dividend amounting to 0 undefined. Dividend means that Zynex distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Sonderdividende
Details
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Zynex provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Zynex’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Zynex's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Zynex Dividend History

DateZynex Dividend
2030e0.02 undefined

Zynex dividend payout ratio

In 2024, Zynex had a payout ratio of 23.58%. The payout ratio indicates the percentage of the company's profits that Zynex distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Zynex represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Zynex could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Zynex's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Zynex Payout Ratio History

DateZynex Payout ratio
2030e23.54 %
2029e23.56 %
2028e23.52 %
2027e23.54 %
2026e23.63 %
2025e23.4 %
202423.58 %
202323.89 %
202222.73 %
202124.13 %
202024.83 %
201924.83 %
201826.92 %
201724.83 %
201624.83 %
201524.83 %
201424.83 %
201324.83 %
201224.83 %
201124.83 %
201024.83 %
200924.83 %
200824.83 %
200724.83 %
200624.83 %
200524.83 %
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Zynex.

Zynex latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-0.2 -0.66  (-229.01 %)2025 Q2
3/31/2025-0.24 -0.33  (-34.8 %)2025 Q1
12/31/20240.09 -0.02  (-121.79 %)2024 Q4
9/30/20240.06 0.07  (21.11 %)2024 Q3
6/30/20240.08 0.04  (-48.85 %)2024 Q2
3/31/20240.03 0  (-100 %)2024 Q1
12/31/20230.17 0.21  (21.11 %)2023 Q4
9/30/20230.1 0.1  (5.04 %)2023 Q3
6/30/20230.05 0.09  (96.08 %)2023 Q2
3/31/20230.01 0.04  (194.12 %)2023 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Zynex stock

Eulerpool World ESG Rating (EESG©)

59/ 100

🌱 Environment

65

👫 Social

57

🏛️ Governance

54

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Zynex shareholders

%
Name
Stocks
Change
Date
47.23677 % Sandgaard (Thomas)14,312,741-1,718,4923/18/2025
3.12779 % The Vanguard Group, Inc.947,720-101,1456/30/2025
1.71162 % Two Sigma Investments, LP518,620246,5876/30/2025
1.66891 % BlackRock Institutional Trust Company, N.A.505,679-583,2976/30/2025
1.45273 % Janney Montgomery Scott LLC440,177291,1346/30/2025
0.81749 % Arrowstreet Capital, Limited Partnership247,698-10,4956/30/2025
0.79843 % Susquehanna International Group, LLP241,924203,6776/30/2025
0.71033 % Millennium Management LLC215,231199,4146/30/2025
0.62512 % Geode Capital Management, L.L.C.189,410-197,5876/30/2025
0.56852 % Renaissance Technologies LLC172,26222,0006/30/2025
1
2
3
4
5
...
10

Zynex Executives and Management Board

Mr. Thomas Sandgaard

(66)
Zynex Chairman of the Board (since 2025)
Compensation 991,810

Ms. Anna Lucsok

(39)
Zynex Chief Commercial Officer
Compensation 709,109

Mr. Barry Michaels

(75)
Zynex Independent Director
Compensation 175,000

Mr. Michael Cress

(67)
Zynex Independent Director
Compensation 170,000

Mr. Joshua Disbrow

(50)
Zynex Independent Director
Compensation 170,000
1
2

Most common questions regarding Zynex

What values and corporate philosophy does Zynex represent?

Zynex Inc represents values of innovation, excellence, and patient-centric care in the medical technology industry. With a corporate philosophy focused on delivering high-quality medical devices and exceptional customer service, Zynex Inc strives to enhance the lives of patients through advanced medical solutions. The company is dedicated to continuously innovating and developing state-of-the-art products that improve healthcare outcomes and patient experiences. Zynex Inc's commitment to excellence has made it a trusted name in the industry, providing effective and reliable medical solutions.

In which countries and regions is Zynex primarily present?

Zynex Inc is primarily present in the United States of America.

What significant milestones has the company Zynex achieved?

Zynex Inc, a leading medical technology company, has achieved several significant milestones. The company successfully introduced NeuroMove, its flagship neuro rehabilitation therapy device, which has revolutionized the industry. Zynex Inc also received FDA approval for their innovative Pain Management products, including NexWave and Infinity Plus, providing advanced pain relief solutions to patients. Furthermore, the company expanded its reach across the United States, establishing a strong presence in the healthcare market. Zynex Inc's consistent focus on research and development, coupled with its commitment to improving patient outcomes, has positioned them as a leading player in the medical technology sector.

What is the history and background of the company Zynex?

Zynex Inc is a reputable company with a rich history and background. Founded in 1996, Zynex has consistently grown and established itself as a leader in the medical technology industry. Specializing in electrotherapy devices, the company offers innovative solutions for pain management and rehabilitation. Zynex has successfully developed and commercialized numerous products that have helped improve the lives of patients worldwide. Their commitment to research and development, along with their dedication to customer satisfaction, has garnered them a strong reputation in the market. With a focus on technological advancements and a mission to enhance patient care, Zynex Inc continues to thrive and make a significant impact in the medical device industry.

Who are the main competitors of Zynex in the market?

The main competitors of Zynex Inc in the market include companies such as Medtronic, Abbott Laboratories, and Neurometrix. These companies also specialize in medical devices and technology, providing similar products and services within the healthcare industry. Zynex Inc competes with these companies to capture market share and meet the needs of healthcare professionals and patients.

In which industries is Zynex primarily active?

Zynex Inc is primarily active in the medical device industry.

What is the business model of Zynex?

Zynex Inc's business model revolves around developing, manufacturing, and marketing non-invasive medical devices and accessories. The company specializes in electrotherapy products that aid in pain management, rehabilitation, and physical therapy. Zynex Inc primarily focuses on three key business segments: electrotherapy, neurological diagnostics, and patient monitoring. With a commitment to innovation and quality, Zynex Inc serves healthcare professionals, patients, and medical institutions with its advanced medical technologies. Through this business model, Zynex Inc aims to improve patient outcomes, enhance quality of life, and contribute to the overall advancement of the medical industry.

What is the P/E ratio of Zynex 2025?

The P/E ratio cannot be calculated for Zynex at the moment.

What is the P/S ratio of Zynex 2025?

The P/S cannot be calculated for Zynex currently.

What is the Quality Investing of Zynex?

The Quality Investing for Zynex is 3/10.

What is the revenue of Zynex 2025?

The expected Zynex revenue is 96.67 M USD.

How high is the profit of Zynex 2025?

The expected Zynex profit is -40.69 M USD.

What is the business model of Zynex

Zynex Inc is a healthcare company based in the United States that specializes in the development and marketing of medical devices and therapy equipment. The company was founded in 1996 and is headquartered in Lone Tree, Colorado. Zynex offers a wide range of products and services for various medical areas. The core areas of Zynex are electrotherapy, pain therapy, orthopedics, and neurology. In these areas, the company develops and produces medical devices such as electronic pain therapy devices, electromyography-guided therapy systems, neurological therapy devices, and custom-fit orthotic systems. Zynex's electrotherapy devices are used for pain relief and muscle stimulation. The devices are easy to use and can be used at home. The range includes portable muscle stimulation devices that relieve joint, back, or neck pain, as well as transcutaneous electrical nerve stimulation (TENS) devices that enable non-invasive pain treatment. Zynex also offers electromyography-guided therapy systems that are used in the rehabilitation after injuries or surgeries. These systems are specifically tailored to the individual needs of the patient and help restore muscle strength and function. In the field of neurology, Zynex offers devices for the treatment of stroke patients, including direct current stimulation systems and electronic muscle stimulation devices. These devices help improve the motor skills of the patients. Zynex's custom-fit orthotic system is an individually tailored orthosis system that provides protection and support for injuries or conditions. The orthotic systems are made from high-quality materials and are tailored to the individual needs of the patient. In addition to developing and manufacturing medical devices, Zynex also offers medical services, such as conducting electromyography tests and providing patients with orthotic aids. Zynex aims to offer medical products that improve patients' quality of life and contribute to their recovery. The company works closely with medical professionals to develop and launch its products on the market. In summary, Zynex Inc is an innovative and versatile company that specializes in the development and marketing of medical devices and therapy equipment. The company offers its customers a wide range of products and services that are tailored to the individual needs of patients. With its high-quality and effective products, Zynex contributes to people leading better and pain-free lives.

What is the Zynex dividend?

Zynex pays a dividend of 0.1 USD distributed over payouts per year.

How often does Zynex pay dividends?

The dividend cannot currently be calculated for Zynex or the company does not pay out a dividend.

What is the Zynex ISIN?

The ISIN of Zynex is US98986M1036.

What is the Zynex WKN?

The WKN of Zynex is A0Q5XP.

What is the Zynex ticker?

The ticker of Zynex is ZYXI.

How much dividend does Zynex pay?

Over the past 12 months, Zynex paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zynex is expected to pay a dividend of -0.11 USD.

What is the dividend yield of Zynex?

The current dividend yield of Zynex is .

When does Zynex pay dividends?

Zynex pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zynex?

Zynex paid dividends every year for the past 1 years.

What is the dividend of Zynex?

For the upcoming 12 months, dividends amounting to -0.11 USD are expected. This corresponds to a dividend yield of -8.09 %.

In which sector is Zynex located?

Zynex is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zynex kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zynex from 1/21/2022 amounting to 0.1 USD, you needed to have the stock in your portfolio before the ex-date on 1/5/2022.

When did Zynex pay the last dividend?

The last dividend was paid out on 1/21/2022.

What was the dividend of Zynex in the year 2024?

In the year 2024, Zynex distributed 0 USD as dividends.

In which currency does Zynex pay out the dividend?

The dividends of Zynex are distributed in USD.

All fundamentals about Zynex

Our stock analysis for Zynex Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zynex Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.